Login
$VSTM
$7.73 +$0.03 (0.39%) After hours

$VSTM SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 Form 4: Paterson Dan, Director

Sold 1,299 shares ($12.5K)

05 Nov 2026 S-3ASR
05 Nov 2026 FORM S-8
05 Nov 2026 8-K: Regulation FD Disclosure

Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION NOVEMBER 2026

05 Nov 2026 10-Q
30 Oct 2026 SCHEDULE 13G/A
14 Oct 2026 8-K: Other Events

Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 30,937,500 shares (the “Shares”) of its common stoc...

14 Oct 2026 424B5
14 Oct 2026 424B5
14 Oct 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +2 more

VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update October 14, 2026

02 Oct 2026 Form 4: Paterson Dan, Director

Disposed of 106,893 shares (Grant/Award Acquisition) · Sold 44,121 shares ($353K)

02 Oct 2026 Form 4: Calkins Daniel, Chief Financial Officer

Disposed of 8,333 shares (Grant/Award Acquisition) · Sold 2,566 shares ($20.5K)

01 Oct 2026 144
23 Sep 2026 Form 4: Calkins Daniel, Chief Financial Officer

Sold 55 shares ($424)

14 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Aug 2026 8-K: Results of Operations and Financial Condition

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million

06 Aug 2026 10-Q
07 Aug 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This Amendment No. 3 to Note Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (“Issuer”), the Persons listed on the signature pages her...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support